Relation between the acute response to salbutamol and long-term FEV1 responses to tiotropium (TIO), formoterol (FORM) and its combination (T+F) in COPD patients Source: Eur Respir J 2003; 22: Suppl. 45, 4s Year: 2003
Lack of effect of promoter, coding and 3‘ polymorphisms of the β2 -adrenergic receptor (ADRB2 ) on the clinical response to salmeterol alone or with fluticasone propionate in subjects with asthma Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008
Dose-related efficacy of vilanterol trifenatate (VI), a long-acting beta2 agonist (LABA) with inherent 24-hour activity, in patients with persistent asthma Source: Annual Congress 2010 - Bronchodilators in airways disease Year: 2010
Bronchodilator response of single dose of tiotropium (Tio) plus formoterol (Formo) versus four doses of ipratopium (Ipra) plus salbutamol (Salb) over 24 hours in subjects with moderate-to-severe stable COPD Source: Annual Congress 2008 - Diagnosing, monitoring and treating respiratory diseases in primary care Year: 2008
Comparison of fluticasone propionate + salmeterol (FP+S) and montelukast (MK) on bronchial reactivity (BR), pulmonary function (PF) and clinical outcome in children with mild asthma Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009
Safety and tolerability of the novel inhaled corticosteroid (ICS) fluticasone furoate (FF) in combination with the long-acting beta2 agonist (LABA) vilanterol (VI) administered once daily (OD) in patients with asthma Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012
Pharmacodynamics (PD) of low and high strength budesonide plus formoterol (BF) Spiromax® and BF Turbuhaler® in healthy volunteers (HV) Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
The influence of β2 adrenoceptor polymorphisms on the response to formoterol, montelukast or higher dose budesonide in patients with uncontrolled asthma despite low dose budesonide Source: Annual Congress 2004 - Further pharmacological and clinical evidence for using long-acting β-agonists with inhaled corticosteroids Year: 2004
Salmeterol/fluticasone combination (SFC) is associated with improved asthma control compared with concurrent long-acting β2 agonists (LABA) and inhaled corticosteroids (ICS) or ICS alone Source: Eur Respir J 2003; 22: Suppl. 45, 235s Year: 2003
A comparison of salmeterol xinafoate (SX) plus beclomethasone dipropionate (BDP) and theophylline (Theo) plus BDP in the treatment of moderate chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2005; 26: Suppl. 49, 292s Year: 2005
Onset of action of salmeterol/fluticasone (SFC) in single inhaler vs. salmeterol (S) in patients with COPD Source: Eur Respir J 2003; 22: Suppl. 45, 285s Year: 2003
Acute effects of higher than customary doses of salmeterol (SM) and salbutamol (SB) in patients with acute exacerbation of COPD Source: Eur Respir J 2001; 18: Suppl. 33, 514s Year: 2001
Sequential flexible therapy with formoterol (Foradil®) plus budesonide (Miflonide®) versus a fixed combination of salmeterol and fluticasone (Seretide®) in asthma self-management Source: Eur Respir J 2002; 20: Suppl. 38, 388s Year: 2002
Safety of fluticasone furoate (FF), an inhaled corticosteroid in combination with vilanterol (VI), a long-acting beta agonist in management of COPD exacerbations Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012
A comparison of salmeterol xinafoate (SX) plus fluticasone propionate (FP) and slow-release theophylline (Theo) plus FP in the treatment of stable chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2006; 28: Suppl. 50, 31s Year: 2006
Synergistic bronchoprotective activity of the long-acting beta 2-agonist olodaterol with tiotropium (long-acting M3 antagonist) and ciclesonide (inhaled steroid) on the ovalbumin-induced bronchoconstriction in anaesthetized guinea pigs Source: Annual Congress 2011 - Understanding disease and drug mechanisms Year: 2011
Clinical effects of adding fluticasone propionate/salmeterol (FSC) and tiotropium (TIO) in severe-to-very severe COPD Source: Annual Congress 2005 - Therapeutic options for COPD: present and future Year: 2005
Tiotropium bromide (TIO) reduces hospitalizations in patients with COPD who had been refractory to treatment with combined inhaled corticosteroid/long acting beta agonist (ICS/LABA) Source: Eur Respir J 2005; 26: Suppl. 49, 717s Year: 2005
Effects of Arg16Gly polymorphism in ADRB2 gene on responses to salmeterol or montelukast added to inhaled corticosteroids in Japanese asthmatic subjects Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012
Onset of action of tiotropium (TIO) + formoterol (FOR) in patients with stable COPD Source: Eur Respir J 2003; 22: Suppl. 45, 285s Year: 2003